Morgan Stanley Resumes Abbott Labs (ABT) at Overweight
More News related to ABT
- Absolute Launches Computrace Mobile Beta Program for BlackBerry(R) Smartphones
- Abbott Labs (ABT) Reaches Settlements in Litigation Related to Direct Purchaser Class Action; to Pay $184M
- Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: NVS, JNJ, PFE, GSK, ABT, AZN
- Holiday travelers beware: Every 50 seconds a laptop goes missing at U.S. airports(1)
- Short Seller Chanos Eyes Medical Sector
More News related to New Coverage
- B. Riley Downgrades Doral Financial (DRL) to Neutral
- CL King Downgrades Ceragon (CRNT) to Accumulate
- Matrix Upgrades/Downgrades for December 1, 2008
- Raymond James Downgrades Allscripts (MDRX) to Market Perform
- RBC Capital Downgrades Strategic Hotels & Resorts (BEE) to Underperform
Morgan Stanley resumes coverage on Abbott Laboratories (NYSE: ABT) with an Overweight rating.
Abbott Laboratories engages in the development, manufacture, and sale of health care products worldwide.
Related Categories
New CoverageStocks Mentioned
-2.24Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
